Neogen Co. (NASDAQ:NEOG) VP Jason Warren Lilly Sells 7,107 Shares

Share on StockTwits

Neogen Co. (NASDAQ:NEOG) VP Jason Warren Lilly sold 7,107 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $72.75, for a total transaction of $517,034.25. Following the transaction, the vice president now owns 18,401 shares in the company, valued at $1,338,672.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jason Warren Lilly also recently made the following trade(s):

  • On Thursday, November 21st, Jason Warren Lilly sold 2,500 shares of Neogen stock. The stock was sold at an average price of $64.61, for a total transaction of $161,525.00.

NEOG opened at $72.76 on Friday. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of 63.16, a PEG ratio of 6.15 and a beta of 1.35. Neogen Co. has a twelve month low of $50.60 and a twelve month high of $79.83. The company’s 50-day moving average price is $68.02 and its two-hundred day moving average price is $68.18.

Neogen (NASDAQ:NEOG) last released its earnings results on Monday, December 23rd. The company reported $0.31 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.32 by ($0.01). The company had revenue of $107.80 million during the quarter, compared to analysts’ expectations of $109.93 million. Neogen had a net margin of 14.35% and a return on equity of 9.17%. The firm’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.31 earnings per share. On average, sell-side analysts expect that Neogen Co. will post 1.17 EPS for the current year.

Several research analysts recently weighed in on the stock. BidaskClub upgraded shares of Neogen from a “hold” rating to a “buy” rating in a report on Thursday. Roth Capital restated a “neutral” rating on shares of Neogen in a report on Tuesday, December 31st. Zacks Investment Research upgraded shares of Neogen from a “sell” rating to a “hold” rating and set a $71.00 price target on the stock in a report on Wednesday, November 27th. Finally, Stephens assumed coverage on shares of Neogen in a report on Monday, February 10th. They set an “overweight” rating and a $88.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $79.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in Neogen by 2.1% in the second quarter. BlackRock Inc. now owns 7,643,175 shares of the company’s stock valued at $474,718,000 after acquiring an additional 160,186 shares during the last quarter. State Street Corp boosted its stake in Neogen by 3.1% in the fourth quarter. State Street Corp now owns 1,655,963 shares of the company’s stock valued at $108,068,000 after acquiring an additional 50,419 shares during the last quarter. Beacon Investment Advisory Services Inc. boosted its stake in Neogen by 2,384.4% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 404,960 shares of the company’s stock valued at $26,428,000 after acquiring an additional 388,660 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Neogen by 4.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 357,358 shares of the company’s stock valued at $23,322,000 after acquiring an additional 16,087 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in Neogen by 12.3% in the third quarter. Parametric Portfolio Associates LLC now owns 175,543 shares of the company’s stock valued at $11,956,000 after acquiring an additional 19,218 shares during the last quarter. Hedge funds and other institutional investors own 91.81% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.

Recommended Story: What is the accumulation/distribution indicator?

Insider Buying and Selling by Quarter for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.